Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

221.79USD
21 Aug 2019
Change (% chg)

-- (--)
Prev Close
$221.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
326,112
52-wk High
$226.31
52-wk Low
$136.47

Select another date:

Fri, Aug 16 2019

UPDATE 1-Edwards Lifesciences, Medtronic heart valves win U.S. approval for expanded use

Aug 16 Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the U.S. FDA said on Friday.

Edwards Lifesciences, Medtronic heart valves win FDA approval for expanded use

Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the FDA said on Friday.

Edwards Lifesciences, Medtronic heart valves win FDA approval for expanded use

Aug 16 Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the FDA said on Friday.

FDA ties three deaths to Edwards Lifesciences' recalled heart devices

The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices.

UPDATE 2-FDA ties three deaths to Edwards Lifesciences' recalled heart devices

July 1 The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices.

FDA says three deaths related to Edwards Lifesciences' recalled heart devices

July 1 The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices.

Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies

Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday.

CORRECTED-Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies

March 16 Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday.

Select another date: